What does this research mean for the field?

[18F]ALF-NOTA-FAPI-04 PET/CT can predict clinical outcomes in patients with recurrent gastric cancer receiving PD-1 inhibitors and chemotherapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To explore the predictive value of [¹⁸F]ALF-NOTA-FAPI-04 PET/CT in assessing outcomes for patients with recurrent gastric cancer treated with PD-1 inhibitors and chemotherapy.

February 27, 2026Open Access

Prognostic Significance of Pretreatment 18 FALF-NOTA-FAPI-04 PET/CT in Patients With Recurrent Gastric Cancer Undergoing Combined PD-1 Inhibitor and Chemotherapy

Puntos clave

To explore the predictive value of [¹⁸F]ALF-NOTA-FAPI-04 PET/CT in assessing outcomes for patients with recurrent gastric cancer treated with PD-1 inhibitors and chemotherapy.
Used [¹⁸F]ALF-NOTA-FAPI-04 PET/CT imaging before treatment.
Monitored clinical outcomes during and after combined PD-1 inhibitor and chemotherapy.
Analyzed the imaging results to determine their correlation with patient outcomes.
The imaging tool demonstrated potential for predicting treatment responses.
Patients showing positive imaging results had better clinical outcomes.
The study suggests improved prognostic evaluation based on imaging findings.

Resumen

¹⁸FALF-NOTA-FAPI-04 PET/CT may be a useful imaging tool for predicting clinical outcomes in patients with recurrent gastric cancer undergoing treatment with PD-1 inhibitors and chemotherapy.

Me gusta

Guardar

Ver artículo completo